Skip to main content
. Author manuscript; available in PMC: 2017 Mar 28.
Published in final edited form as: Leukemia. 2016 Sep 28;31(3):678–687. doi: 10.1038/leu.2016.260

Figure 2. Treatment with JQ1 depletes the expression levels of pSTAT5, c-MYC, CDK4 and CDK6 with concomitant induction of HEXIM1 and BIM expression levels in sAML cells.

Figure 2

A. HEL92.1.7 cells were treated with JQ1 for 24 hours, and then analyzed by reverse phase protein analysis. Figure shows log2 fold change of selected targets in JQ1-treated cells relative to the untreated control cells. All fold changes shown are significant (p<0.05). B-C. HEL92.1.7 and SET-2 cells were treated with the indicated concentrations of JQ1 for 24 hours. Total cell lysates were prepared and immunoblot analyses were conducted as indicated. The expression levels of β-Actin in the lysates served as the loading control.